Keywords: Multiple sclerosis, Single nucleotide polymorphisms, Nabiximols, Spasticity, ABCB1 Authors: Alessandra Gemma, Marco Mauri, Paola Banfi, Maurizio Versino, Alen Zollo,…
Abstract Introduction: Multiple Sclerosis (MS) is associated with a wide range of debilitating symptoms, and conventional therapies often fail to…
Abstract Background: One of the most disabling symptoms of patients with multiple sclerosis (MS) is spasticity which affects their quality…
Abstract Background: Cannabinoid oro-mucosal spray nabiximols is approved for patients with moderate to severe multiple sclerosis spasticity (MSS) resistant to…
Abstract Aim: Cannabis-based medication has recently been made available in the NHS for reducing pain and spasticity in patients with…
Abstract Background: Over 80% of individuals with multiple sclerosis (MS) experience MS-associated spasticity (MSS). In many European countries, after failure…
Abstract Patients with multiple sclerosis (MS) and spinal cord injury (SCI) commonly sustain central neuropathic pain (NP) and spasticity. Despite…
Abstract Objectives: Nabiximols represents an increasingly employed add-on treatment option for spasticity in people with multiple sclerosis (PwMS) who either…
Abstract In patients with multiple sclerosis (MS), a typical pattern of muscle tone alteration, known as spasticity, is frequently observed…
Abstract Background: Multiple sclerosis (MS) treatment has radically improved over the last years; however, MS symptom management is still challenging.…